| Market Cap | 2.07B | P/E | - | EPS this Y | 91.70% | Ern Qtrly Grth | - |
| Income | -87.97M | Forward P/E | -77.36 | EPS next Y | 1,500.00% | 50D Avg Chg | -4.00% |
| Sales | 591.64M | PEG | -9.11 | EPS past 5Y | 33.63% | 200D Avg Chg | 17.00% |
| Dividend | N/A | Price/Book | 2.12 | EPS next 5Y | 151.20% | 52W High Chg | -21.00% |
| Recommedations | 1.90 | Quick Ratio | 5.67 | Shares Outstanding | 127.67M | 52W Low Chg | 171.00% |
| Insider Own | 1.18% | ROA | -3.50% | Shares Float | 125.95M | Beta | 1.10 |
| Inst Own | 101.04% | ROE | -9.07% | Shares Shorted/Prior | 7.24M/7.01M | Price | 16.25 |
| Gross Margin | 41.34% | Profit Margin | -14.87% | Avg. Volume | 885,233 | Target Price | 21.55 |
| Oper. Margin | -11.17% | Earnings Date | Apr 30 | Volume | 1,223,347 | Change | -7.38% |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
| Piper Sandler | Overweight | Feb 26, 24 |
| Goldman Sachs | Buy | Feb 22, 24 |
| Needham | Buy | Feb 21, 24 |
| TD Cowen | Outperform | Dec 29, 23 |
| BTIG | Buy | Dec 29, 23 |
| Needham | Buy | Dec 28, 23 |
| Morgan Stanley | Equal-Weight | Nov 8, 23 |
| Needham | Buy | Nov 7, 23 |
| Morgan Stanley | Equal-Weight | Oct 24, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director Director | May 22 | Option | 11.60 | 1,507 | 17,481 | 56,174 | 05/24/23 |
| TETRAULT LYNN A. | Director Director | May 18 | Option | 7.27 | 3,334 | 24,238 | 39,111 | 05/20/22 |
| Bonello William | Chief Financial Offi.. Chief Financial Officer | Apr 28 | Option | 7.52 | 5,727 | 43,067 | 191,548 | 05/02/22 |
| Bonello William | Chief Financial Offi.. Chief Financial Officer | Mar 07 | Option | 7.52 | 5,000 | 37,600 | 103,516 | 03/09/22 |
| Bonello William | Chief Financial Offi.. Chief Financial Officer | Mar 07 | Sell | 18.29 | 3,209 | 58,693 | 98,516 | 03/09/22 |
| McKenzie Kathryn B | Chief Sustainability.. Chief Sustainability/Risk Ofcr | Jan 11 | Option | 9.07 | 2,100 | 19,047 | 49,361 | 01/12/22 |
| McKenzie Kathryn B | Chief Financial Offi.. Chief Financial Officer | Dec 21 | Option | 9.07 | 5,000 | 45,350 | 16,689 | 12/23/21 |
| McKenzie Kathryn B | Chief Financial Offi.. Chief Financial Officer | Dec 21 | Sell | 35 | 1,846 | 64,610 | 11,689 | 12/23/21 |
| SHOVLIN ROBERT J. | President, Clinical.. President, Clinical Services | May 27 | Option | 18.65 | 126,958 | 2,367,767 | 280,705 | 05/27/21 |
| SHOVLIN ROBERT J. | President, Clinical.. President, Clinical Services | May 27 | Sell | 39.31 | 130,604 | 5,134,043 | 150,101 | 05/27/21 |
| Weiss Lawrence Martin | Chief Medical Office.. Chief Medical Officer | Apr 26 | Option | 19.05 | 25,050 | 477,202 | 130,847 | 04/26/21 |
| JONES STEVEN C | Director Director | Dec 14 | Sell | 50.83 | 70,000 | 3,558,100 | 1,000,000 | 12/14/20 |
| BALLIET JENNIFER | VP and Chief Culture.. VP and Chief Culture Officer | Dec 11 | Option | 8.03 | 15,000 | 120,450 | 39,980 | 12/11/20 |
| BALLIET JENNIFER | VP and Chief Culture.. VP and Chief Culture Officer | Dec 11 | Sell | 49.99 | 15,000 | 749,850 | 24,980 | 12/11/20 |
| JONES STEVEN C | Director Director | Dec 07 | Sell | 48.52 | 130,000 | 6,307,600 | 1,070,000 | 12/07/20 |
| Bonello William | President, Informati.. President, Informatics | Dec 04 | Option | 8.03 | 8,000 | 64,240 | 20,060 | 12/04/20 |
| Bonello William | President, Informati.. President, Informatics | Dec 04 | Sell | 46.8 | 8,000 | 374,400 | 12,060 | 12/04/20 |
| CARDOZA GEORGE | President, Pharma Se.. President, Pharma Services | Nov 25 | Option | 7.52 | 150,000 | 1,128,000 | 447,976 | 11/25/20 |
| CARDOZA GEORGE | President, Pharma Se.. President, Pharma Services | Nov 25 | Sell | 45.34 | 130,000 | 5,894,200 | 370,902 | 11/25/20 |
| VAN OORT DOUGLAS M | Chairman and CEO Chairman and CEO | Nov 16 | Option | 7.52 | 500,000 | 3,760,000 | 2,522,790 | 11/16/20 |
| VAN OORT DOUGLAS M | Chairman and CEO Chairman and CEO | Nov 16 | Sell | 42.03 | 340,000 | 14,290,200 | 2,422,790 | 11/16/20 |
| JONES STEVEN C | Director Director | Sep 30 | Sell | 36.6 | 280,000 | 10,248,000 | 97,932 | 09/30/20 |
| CROWTHER BRUCE K | Director Director | Sep 24 | Option | 9.11 | 8,333 | 75,914 | 54,816 | 09/24/20 |
| CROWTHER BRUCE K | Director Director | Sep 24 | Sell | 35.35 | 10,733 | 379,412 | 46,483 | 09/24/20 |